Audience: Call Centers Location: Benefits/A-Z List Updated: 6.26.20

Reviewed: 6.26.20

## Cytochrome P450 (CYP450) Variant Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4)

#### Also known as

- 1. AG® CYP kits
- 2. AmpliChip® CYP450 Test
- 3. GeneSight Psychotropic
- 4. INFINITI CYP2C19 Assay
- 5. Mental Health DNA Insight
- 6. PersonaGene™ Genetic Panel
- 7. STA2R SureGene Test
- 8. Verigene CYP2C19 Nucleic Acid Test
- YouScript Panel

#### Description

Cytochrome P450 (CYP450) variant genotyping is a genetic test intended primarily to predict an individual's response to a drug. CYP450 is a family of over 60 enzymes, which are responsible for the metabolism of a significant proportion of currently administered drugs. The activity of CYP450 enzymes varies among individuals and can be influenced by a number of factors, including inherited variations in the CYP450 genes, diet, concurrent medications, ethnicity, gender, overall health, age, and other environmental factors. Based on the results of CYP450 genotyping for drug metabolism, individuals are categorized as ultra-rapid, intermediate or poor metabolizers. In theory, this should lead to early selection and optimal dosing of the most effective drugs, while minimizing treatment failures, serious adverse drug reactions, and medical costs.

#### See also

Similar, related, or easily confused documents.

- <u>Genetic and Pharmacogenetic Testing</u> Provides information about a person's genes and chromosomes.
- <u>Genetic Counseling</u> Helping people understand and adapt to the implications of genetic contributions to disease.
- Pharmacogenetic Testing of the VKORC1 Gene for Warfarin Response A
   DNA test on a patient's blood or saliva to predict their response to
   warfarin (Coumadin), an orally administered anticoagulant drug, or
   commonly referred to as a blood thinner.



#### Commercial

A Coverage Policy, Cytochrome P450 (CYP450) Variant Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4), is on medica.com.

• Considered investigative, not covered.

### Government Programs

Refer to the table below.

Plan	Coverage				
AccessAbility	Medicaid only groups:				
(SNBC),	• Refer to <u>Medicaid</u> below.				
Minnesota					
Senior Care	Medicare eligible groups:				
Plus (MSC+)	Considered investigative, not covered.				
Follows Medicare guidelines.					
	If no Medicare eligibility, Medicaid applies. Refer to				
	Medicaid below.				
AccessAbility	A Coverage Policy, Cytochrome P450 (CYP450) Variant				
Enhanced	Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2,				
(SNBC SNP),	CYP3A4), is on medica.com.				
DUAL (MSHO) • Considered investigative, not covered.					
Advantage	A Course Policy Cotook your PASO (CVPASO) Versions				
Advantage	A Coverage Policy, Cytochrome P450 (CYP450) Variant     Constraint (CYP3DE CYP3C0 CYP3C10 CYP1A3)				
	Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4), is on medica.com.				
	Considered investigative, not covered.				
	Considered investigative, not covered.				
Advantage	A Coverage Policy, Cytochrome P450 (CYP450) Variant				
PartnerCare	Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2,				
(I-SNP)	CYP3A4), is on medica.com.				
	Considered investigative, not covered.				



# Government Programs, continued

Plan	Coverage		
Medicaid (SPP)	<ul> <li>A Coverage Policy, Cytochrome P450 (CYP450) Variant Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4), is on medica.com.</li> <li>Considered investigative, not covered.</li> </ul>		
Prime	<ul> <li>Medicare does not have a policy. Medica's Coverage Policy, Cytochrome P450 (CYP450) Variant Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4), on medica.com applies.</li> <li>Considered investigative, not covered</li> <li>Follows Medicare guidelines.</li> </ul>		
Select, Signature	<ul> <li>Considered investigative, not covered.</li> <li>Follows Medicare guidelines.</li> </ul>		

#### Individual and Family Business (IFB)

A Coverage Policy, *Cytochrome P450 (CYP450) Variant Genotyping (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4)*, is on <a href="medica.com">medica.com</a>.

• Considered investigative, not covered.

#### Medica Health Plan Solutions (MHPS)

Coverage depends on the employer AND servicing provider.

Employer	Provider	Coverage	
Mayo Medical Plan	Mayo provider	Covered based on place of service. Quote office visit or outpatient hospital benefits.	
Mayo Medical Plan	Non- Mayo provider	<ul> <li>A Coverage Policy, Cytochrome P450 (CYP450)         Variant Genotyping (CYP2D6, CYP2C9,         CYP2C19, CYP1A2, CYP3A4), is on medica.com.</li> <li>Considered investigative, not covered.</li> </ul>	
All others	All providers	<ul> <li>A Coverage Policy, Cytochrome P450 (CYP450)         Variant Genotyping (CYP2D6, CYP2C9,         CYP2C19, CYP1A2, CYP3A4), is on medica.com.</li> <li>Considered investigative, not covered.</li> </ul>	

National Account Member Services (NAMS)

A Medical Policy, *Genetic Testing*, is on <u>UHC Provider.com</u>.

- May be listed separately, if so, quote from iBAAG.
- If not listed separately, considered investigative, not covered.

### Document history

The document history for the past 12 months is outlined below.

**Note**: See the KN for complete document history. Email questions to <a href="mailto:CSKNupdate@medica.com">CSKNupdate@medica.com</a>.

Date	Description		
6.26.20	Re-review due to age.		
6.5.20	Updated to new template.		
6.5.20	Updated MMP for CP to indicate depends on provider.		
10.19.19	Updated to new template.		



Applicability  Business Segments						
■ All □ Assoc. □ Comm. □ IFB □ Medicare □ Medicaid □ MHPS □ My Plan □ PSC						
Specific Clients/Products						
■ All □ Other:						
System						
☐ HealthRules Payor ☐ ISET (Choose an item.) ■ N/A ☐ Other:						
Departments						
☐ All ☐ Billing ■ Call Center ☐ Claims ☐ Enrollment ☐ Payment Integrity ☐ Other:						
Approved By	Document Owner	Date				
A-Z Review Team	KNTWs	6.26.20				